Ikarian Capital LLC Acquires Shares of 258,279 Evolus, Inc. (NASDAQ:EOLS)

Ikarian Capital LLC acquired a new stake in Evolus, Inc. (NASDAQ:EOLS) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 258,279 shares of the company’s stock, valued at approximately $4,184,000.

Several other institutional investors also recently bought and sold shares of the business. California State Teachers Retirement System grew its holdings in Evolus by 1.6% in the first quarter. California State Teachers Retirement System now owns 48,109 shares of the company’s stock valued at $674,000 after purchasing an additional 739 shares during the period. Essex Investment Management Co. LLC grew its holdings in Evolus by 0.4% in the third quarter. Essex Investment Management Co. LLC now owns 295,553 shares of the company’s stock valued at $4,788,000 after purchasing an additional 1,111 shares during the period. Arizona State Retirement System grew its holdings in Evolus by 9.4% in the second quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock valued at $158,000 after purchasing an additional 1,253 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Evolus by 4.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 39,882 shares of the company’s stock valued at $559,000 after purchasing an additional 1,637 shares during the period. Finally, Creative Planning grew its holdings in Evolus by 23.7% in the third quarter. Creative Planning now owns 15,451 shares of the company’s stock valued at $250,000 after purchasing an additional 2,963 shares during the period. 90.69% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Sandra Beaver sold 3,276 shares of Evolus stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the transaction, the chief financial officer now owns 148,502 shares in the company, valued at approximately $2,224,559.96. This trade represents a 2.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 6.10% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have recently weighed in on EOLS. Barclays raised their target price on Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. HC Wainwright restated a “buy” rating and issued a $27.00 target price on shares of Evolus in a research report on Thursday, November 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a research report on Monday, September 16th. Finally, Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Friday, September 13th.

Evolus Stock Down 0.3 %

Evolus stock traded down $0.04 during trading on Tuesday, reaching $13.47. 8,945 shares of the company were exchanged, compared to its average volume of 592,029. Evolus, Inc. has a 52-week low of $9.38 and a 52-week high of $17.82. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The stock’s 50 day simple moving average is $15.22 and its two-hundred day simple moving average is $13.88.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.